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ObjectivOs: Evaluar el impacto sobre el presupuesto anual de salud de Chile por la 
inclusión de Daclatasvir/Asunaprevir (DCV/ASV) para el tratamiento de la Hepatitis 
C genotipo 1b. MetOdOlOgíAs: Se modeló la cohorte de pacientes Chilenos con 
Hepatitis C genotipo 1b utilizando datos de prevalencia e incidencia locales de acu-
erdo a la metodología sugerida por la guía de buenas prácticas ISPOR. Se comparó el 
escenario en el que todos los pacientes reciben Peginterferon/Ribavirina (PR) versus 
el escenario donde todos los pacientes son tratados con DCV/ASV. El análisis fue 
realizado desde la perspectiva del sistema de salud público Chileno asumiendo 100% 
de cobertura de los fármacos. Se introdujeron costos asociados al tratamiento farma-
cológico, de eventos adversos, recursos relevantes (monitoreo mediante exámenes 
de laboratorio, anatomía patológica, imágenes y controles médicos) y costos asocia-
dos a complicaciones de la enfermedad. Se consideró un horizonte de tiempo de 5 
años. ResultAdOs: El impacto sobre el presupuesto anual (tomando como base el 
de 2015) se presenta para tres precios posibles de DCV/ASV. A CL$1.500.000 pesos 
chilenos (CL$) semanales se requieren CL$42.928.668.276 adicionales el primer año 
(tratamiento de casos prevalentes) lo que equivale a un 0.71% del presupuesto anual. 
Desde el año 2 en adelante (asumiendo tratar sólo casos incidentes) el monto asciende 
a CL$8.031.019.832 adicionales (0,13% del presupuesto nacional 2015). A CL$1.000.000 
semanal, se requieren CL$25.015.902.617 adicionales el primer año y CL$4.679.931.106 
adicionales desde el año 2 (0,11% y 0,6% del presupuesto anual de salud 2015). A 
CL$500.000 semanales se requieren CL$ 7.103.136.957 adicionales el primer año y 
CL$1.328.842.381 adicionales a partir del segundo año (0,3% y al 0,057% del presu-
puesto nacional 2015 respectivamente). cOnclusiOnes: En los rangos de precios 
estudiados, el impacto sobre el presupuesto de salud chileno oscila entre el 0,3% y 
0,71% para el primer año, el cual disminuiría a menos del 0,15% desde el segundo año.
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Inflammatory bowel disease (IBD) is associated with high costs, high morbidity and 
decreased quality of life in patients. In Mexico and Brazil, there is no concise data 
about prevalence of Crohn´s Disease (CD) estimated to range from 0.0008% to 1.11% 
and no cost data attributable to IBD.Objectives: To assess the average annual cost per 
patient with CD treated with biologics from the perspective of the government health-
care system both in Mexico and Brazil. MethOds: Biologic treatments examined 
included certolizumab pegol (CZP) 400 mg weeks 0, 2, 4 and then every 4 weeks; adali-
mumab (ADA) 160 mg week 0, 80 mg week 2 and then 40 mg every 2 weeks; infliximab 
(INF) 5 mg / kg at weeks 0, 2, 6, and every 8 weeks thereafter. Medication acquisition 
costs were assessed for CZP and ADA, while costs for INF assessed both acquisition 
and administration (infusion). Average weight per patient in the analyses was 70kg. 
Prices were obtained from the Mexican Social Security Institute (IMSS) and ANVISA 
for Brazil. Exchange rates were obtained from public sources (1USD= 0.0675MXN; 
1USD= 2.7BRL). Results: The analysis for Mexico shows lower costs in the first year 
of treatment (induction and maintenance) with CZP (USD$7,719/year) vs ADA and INF 
(USD$12,792, USD$17,313/year, respectively), leading to cost savings per patient/year 
compared with CZP of approximately USD$5,073 and USD$9,594 versus adalimumab 
and infliximab. In Brazil, similar Resultswere seen: CZP (USD$7,186/year) versus ADA 
(USD$24,813/year) and INF (USD$31,004/year), showing savings with CZP of USD$17,627 
vs ADA and USD$23,818 vs INF per year. The savings are even greater with CZP in the 
maintenance years. cOnclusiOns: Certolizumab pegol shows savings when com-
pared to adalimumab and infliximab in the first year of treatment and maintenance, 
which can lead to an important impact on institutional budgets.
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Objectives: Comparing efficacy and costs of treatment strategies using terli-
pressin or noradrenaline for cirrhotic patients with hepatorenal syndrome, under 
the perspectives of Brazilian public health system, a major general hospital and a 
major private health insurance. MethOds: Comparison of efficacy was performed 
through a systematic review with meta-analysis of randomized controlled trials, 
using random-effects model. Economic evaluation was performed through cost-
minimization. Results: Four studies (154 patients) were included in the meta-
analysis. There was no evidence of difference between treatments with terlipressin 
or noradrenaline regarding 30-day survival (risk ratio of 1.04, 95% confidence inter-
val of 0.84-1.30, p= 0.70). Under the perspective of the public health system, costs of 
treatments with terlipressin or noradrenaline were 287.77 and 2,960.45 International 
Dollars (Int$) respectively. Under the perspective of the general hospital, costs of 
the treatments with terlipressin or noradrenaline were Int$7,437.04 and Int$8,406.41 
respectively. Regarding the perspective of the private health insurance, costs of treat-
ments with terlipressin and noradrenaline were Int$13,484.57 and Int$15,061.01 
respectively. cOnclusiOns: There was no evidence of superiority between treat-
ment strategies using terlipressin or noradrenaline regarding survival of patients 
with hepatorenal syndrome, but the strategy using terlipressin was more economical 
under three different perspectives.
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demographics. Results: The total number of CAM users were 148, out of which 
87 (58.8%) were females and 61 (41.2%) were males. Most of the participants (n= 51, 
34.5%) were uneducated and belongs to large families (n= 89, 60.1%). Most of par-
ticipants use CAM to lower their glycemic level, majority (n= 125, 84.5%) of which 
belief that CAM can lower their sugar level. However, only 12% of the participants 
disclose this CAM use to their physician. cOnclusiOns: The finding of current 
study indicates that most of diabetic CAM users population belief that CAM can con-
trol their glycemic level. However, the rate of CAM disclosure to physician was very 
low. Efforts should be made to encourage their diabetic CAM user to disclose their 
CAM use to their physician so he will give them better advise for gycemic control.
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Objectives: The study aims were to investigate patient’s preferences in clinical 
outcomes and patient burden to administer insulin injections, as measured by 
patients’ willingness to pay (WTP). MethOds: Existing national email panels in 
Argentina, Brazil, Chile, Colombia and Mexico were used to collect survey-based 
data from adults > 18 years with type 2 diabetes (T2DM) treated with insulin injec-
tions. Resultswere analysed using a standard choice model designed for discrete 
choice experiment (DCE). Clinical outcomes related to efficacy (reduction in HbA1c) 
and safety (severe (SH) and non-severe hypoglycaemic (NSH) events and change in 
weight) and the patient burden of insulin administration (preparation of insulin 
prior to injecting and number of daily injections) were found to be relevant fac-
tors in qualitative research in patients and were examined in the DCE. Results: 
A total of 1537 people (54% males) with T2DM completed the survey. Participants 
placed high monetary value on efficacy and safety outcomes; they would pay 74 
USD/month to reduce HbA1c by 1% and 80 USD/month to reduce one SH event per 
year. To reduce one NSH per week participants were willing to pay 91 USD/month. 
Participants wanting to lose weight reported a WTP of 37 USD/month to lose 3 kg. 
To avoid preparation of insulin prior to injection, participants reported a WTP of 18 
USD/month and the WTP/month for one fewer injection/day was 25 USD. Potential 
limitations of this study are that preferences expressed may not match preferences 
in real-life situations, and bias through recruiting via internet panels since these 
may not be representative of typical patients. cOnclusiOns: Clinical outcomes 
and administrative burden were significant predictors of choice in people with 
T2DM. Reducing HbA1c as well as number of SH and NSH were the highest valued 
outcomes. In addition, the administrative burden of insulin injections was also 
considered important.
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Objectives: Patient education is a key component for the management of acute 
and chronic conditions. However, majority of such educational sessions are reported 
from the healthcare settings. The present study therefore, aims to evaluate whether 
a home-based intervention can result in better understanding about Diabetes 
Mellitus Type 2 and can increase medication adherence to the prescribed thera-
pies. MethOds: A non-clinical randomized control trial was conducted whereby 
participants received a home-based educational intervention through a registered 
pharmacist. Diabetes knowledge and medication adherence were measured by 
means of self-administered questionnaires. Descriptive statistics were used to 
describe the demographic and disease characteristics of the patients. Inferential 
statistics were used for inter- and intra- group comparisons. SPSS 18 was used 
for data analysis. P< 0.05 was taken as significant. Results: One hundred and 
fifty patients were randomly assigned to two groups (75 patients in each arm). No 
significant differences were observed in either group for demographic variables. 
There was, however, a significant increase in the participants’ levels of knowledge 
about Diabetes Mellitus type 2 and medication adherence among the Home-based 
intervention group at the completion of the intervention (p< 0.001). Significantly 
lower HbA1c levels were also observed among the Home-based intervention group 
after completion of the intervention (p< 0.001). cOnclusiOns: Pharmacist-led 
home-based intervention can significantly increase disease-related knowledge 
and medication adherence in patients with type 2 diabetes mellitus. This study 
hereby concludes that home-based interventional programs should be utilized as 
a compelling method of patient education and counselling.
GAstroIntestInAl dIsorders – Cost studies
PGI1
estudIo de ImPACto PresuPuestAl de dAClAtAsvIr AsoCIAdo A 
AsunAPrevIr desde lA PersPeCtIvA del sIstemA de sAlud PublICo 
ChIleno
Vargas C1, Giglio A2, Soza A3, Espinoza MA4
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Complejo Asistencial Sótero del Río, 
Santiago, Chile, 3Pontificia Universidad Católica de Chile, Santiago, Chile, 4Catholic University of 
Chile, Santiago, Chile
